Vimarsana
Biggest News Aggregation in the World

Page 17 - Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nsclc Today - Breaking & Trending Today

Medicaid Expansion May Decrease Early Mortality in Some With NSCLC - Vimarsana News

Medicaid Expansion May Decrease Early Mortality in Some With NSCLC

Rates of early mortality from NSCLC decreased in states with Medicaid expansion, according to recent research.

EU Approval Sought for Frontline Lazertinib Plus Amivantamab in EGFR+ NSCLC - Vimarsana News

EU Approval Sought for Frontline Lazertinib Plus Amivantamab in EGFR+ NSCLC

A marketing authorization application seeking the approval of the combination of lazertinib and amivantamab in the first-line treatment of adult patients with advanced non­–small cell lung cancer harboring EGFR mutations has been submitted to the European Medicines Agency.

Expert Analysis on Recent Developments in DESTINY-Lung01 and DESTINY-Lung02 Trials - Vimarsana News

Expert Analysis on Recent Developments in DESTINY-Lung01 and DESTINY-Lung02 Trials

Edgardo Santos, MD, FACP, FCCP, analyzes the recent developments in the DESTINY-Lung01 and DESTINY-Lung02 trials, specifically focusing on HER2+ NSCLC patients with brain metastases and exploring the potential impact on clinical practice.

Wakelee Addresses NSCLC Treatment Considerations From Every Angle - Vimarsana News

Wakelee Addresses NSCLC Treatment Considerations From Every Angle

Giving a glimpse into significant data and highlighting the importance of balancing toxicities with efficacy as the non–small cell lung cancer treatment paradigm shifts.

Advances in Dual Immunotherapy Approaches for NSCLC: Data Highlights 2023 - Vimarsana News

Advances in Dual Immunotherapy Approaches for NSCLC: Data Highlights 2023

Eduardo Santos, MD, FACP, FCCP, discusses recent advances in dual immunotherapy approaches for NSCLC, highlighting data from the CheckMate 9LA study.